-
Apple CEO Tim Cook gives nod to founder Steve Jobs in final memo
-
Fils upset by resurgent Tsitsipas at US Open
-
Russian finance minister makes unexpected appearance at G20
-
Trump says AI data center opponents want to be 'backwards and poor'
-
Happy to be back in NY, Sabalenka advances
-
Pakistan ditch coaches, send seven players home after England defeats
-
Naomi Watts to receive lifetime award at top Spain film fest
-
Galliano pulls Met Gala exhibit after antisemitism backlash
-
Jury hears closing arguments in Tupac Shakur murder trial
-
Afghan people should 'not be abandoned': top Red Cross official
-
Pakistan sack coach, send seven players home after England defeats
-
Six defining moments of Lionel Messi's Argentina career
-
New storms threaten Grand Canyon flood search, 2 bodies recovered
-
Trump blasts US backlash against data centers
-
France takes aim at ultra-fast fashion with new levy
-
It 'hurts' says Messi of decision to retire from international football
-
Tribunal says India cannot withdraw from water treaty with Pakistan
-
Benzema ends brief stint with Al Hilal in Saudi league
-
John Galliano pulls US exhibition after antisemitism backlash
-
Djokovic's Grand Slam future uncertain after brutal US Open defeat
-
French Top 14 boss offers 'no guarantees' for first Club World Cup
-
Turkey says regional defence pact not against any country
-
Munoz reunites with Glasner after joining Forest from Palace
-
US vows to keep economic pressure on Iran as G20 finance talks begin
-
Liverpool sign Barcola from PSG for £124 million
-
Shein valued at $26.3 bn in Hong Kong market debut
-
Putin, Xi hold talks in Kyrgyzstan as regional summit begins
-
Crude prices rise above $90 per barrel on US-Iran strikes
-
ChatGPT becomes first AI chatbot to face tougher EU rules
-
Liverpool sign Barcola from PSG for reported £124 million
-
Man City sign Palmeiras winger Allan on five-year deal
-
Putin, Xi, Iran's Pezeshkian in Kyrgyzstan for summit
-
More flooding feared at Grand Canyon after storm leaves 15 missing
-
Fully Permitted Tanzanian Gold Project Clears Path to Construction as Financing, EPCM Fall in Place (LVGLF)
-
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
-
EdWealth Announces MoneyBench Benchmark Comparing AI Money Answers From Ed, ChatGPT and Gemini
-
MEXC Data: BTC Breaks $80,000, Major-Asset Spot Trading Volume Surges 300%
-
Root says new balls behind batsmen's struggles in England
-
G20 finance talks open as US seeks to ramp up pressure on Iran
-
Swollen rivers, washed-out roads hamper Nepal rescue effort
-
Solving Agent Sprawl: The Case for Enterprise Orchestration
-
In France's north, winegrowers bet on a warmer future
-
Springboks switch Kolbe to full-back for third All Blacks Test
-
Deadly virus stalks South Africa's sardines
-
Malaysia's Sarawak eyes cloud seeding as haze worsens
-
South Korea women's football body probes 'period' insult
-
World leaders need to see rising oceans in Pacific: UN official
-
Transitional Fashion Essentials for Autumn: Key Pieces from M&S and Joe Browns
-
Xiaomi Pad 9 Pro Leak Suggests 12.5-Inch Display and Massive Battery
-
China's Xi and Iran's Pezeshkian in Kyrgyzstan, Putin expected
Relief Therapeutics Advances Publication of 2025 Half-Year Report
GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025 half-year report. Originally scheduled for release on August 27, 2025, the report will now be published on August 14, 2025, ahead of market opening.

The change in publication date is due to the Company's anticipated early completion of the report. The half-year report, which will include a shareholder update and interim financial statements, will be available on Relief's website at the time of publication.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
[email protected]
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
H.Gonzales--AT